Reversed Chloroquines as Antimalarial Agents

逆转氯喹作为抗疟药

基本信息

  • 批准号:
    7371986
  • 负责人:
  • 金额:
    $ 21.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-03-15 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The intent of the work presented in this proposal is to address the worldwide health problem brought on by the spread of chloroquine-resistant malaria. An orally available and inexpensive class of replacement drugs termed "reversed chloroquines" (RCQs) is proposed which are expected to act against both chloroquine- resistant and chloroquine-sensitive malaria. Specifically, the following goals are proposed for this research: Goal 1. To understand how to optimize structural features in the next-generation set of RCQ molecules. This will be accomplished by producing a panel of varied RCQ structures, and then testing them against chloroquine-sensitive and chloroquine-resistant malaria, as well as for solubility, central nervous system receptor activity, and cytotoxicity. The most promising candidates will then be evaluated as orally available drugs against malaria in mice. Goal 2. To assess the RCQ mode(s) of action. This will be accomplished by design and testing of RCQ variants which have strategic alterations to the RCQ structures to probe for specific aspects of their action against malaria, by spectroscopic investigations of interactions between heme and RCQs, by inhibition of hemozoin formation, and by measuring the effects on CQ accumulation/efflux of co-administered CQ. After having established the feasibility of the RCQ molecular design, as well providing fundamental understanding of correlations between molecular features and efficacy of RCQs against malaria, the RCQ structures will be "tuned" in order to optimize practical aspects of their use in humans. Although we are directing this study specifically against Plasmodium falciparum, the most problematic human malaria variant, RCQs should also be effective against red blood cell stages of the other human malarias. Malaria is a disease that infects almost half a billion people annually, and kills between one and three million, most of whom are either children or pregnant women. The impact of malaria is increasing, partly because the parasite that causes malaria has evolved into strains that are resistant to our best drugs for treating the disease. This work outlined for this project is to produce and test novel drugs that are designed to circumvent this resistance, as well as to elucidate the way(s) in which these novel drugs work.
描述(由申请人提供):本提案中提出的工作意图是解决抗氯喹疟疾传播带来的全球健康问题。提出了一种可口服且价格低廉的替代药物,称为“反向氯喹”(RCQs),预计可用于治疗氯喹耐药和氯喹敏感型疟疾。具体而言,本研究提出以下目标:目标1。了解如何优化下一代RCQ分子的结构特征。这将通过生产一组不同的RCQ结构来完成,然后测试它们对氯喹敏感和氯喹耐药疟疾的作用,以及溶解度、中枢神经系统受体活性和细胞毒性。然后,最有希望的候选药物将作为口服的抗疟疾药物在小鼠中进行评估。目标2。评估RCQ的行动模式。这将通过设计和测试对RCQ结构进行战略性改变的RCQ变体来实现,以探索其抗疟疾作用的具体方面,通过对血红素和RCQ之间相互作用的光谱研究,通过抑制血色素形成,以及通过测量对CQ积累/流出的影响。在确定了RCQ分子设计的可行性,并对RCQ分子特征与抗疟疾功效之间的相关性提供了基本的理解之后,RCQ结构将被“调整”,以优化它们在人类中的实际应用。虽然我们的研究是专门针对恶性疟原虫(最具问题的人类疟疾变体),但RCQs也应该对其他人类疟疾的红细胞阶段有效。疟疾是一种每年感染近5亿人的疾病,造成100万至300万人死亡,其中大多数是儿童或孕妇。疟疾的影响正在增加,部分原因是导致疟疾的寄生虫已经进化成对我们治疗这种疾病的最佳药物具有抗药性的菌株。本项目概述的工作是生产和测试旨在规避这种耐药性的新药,以及阐明这些新药的工作方式。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID H PEYTON其他文献

DAVID H PEYTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID H PEYTON', 18)}}的其他基金

Preclinical development of novel small molecule malaria drugs that overcome drug
克服药物障碍的新型小分子疟疾药物的临床前开发
  • 批准号:
    8837558
  • 财政年份:
    2011
  • 资助金额:
    $ 21.48万
  • 项目类别:
Preclinical development of novel small molecule malaria drugs that overcome drug
克服药物障碍的新型小分子疟疾药物的临床前开发
  • 批准号:
    8317596
  • 财政年份:
    2011
  • 资助金额:
    $ 21.48万
  • 项目类别:
Preclinical development of novel small molecule malaria drugs that overcome drug
克服药物障碍的新型小分子疟疾药物的临床前开发
  • 批准号:
    8129857
  • 财政年份:
    2011
  • 资助金额:
    $ 21.48万
  • 项目类别:
Preclinical development of novel small molecule malaria drugs that overcome drug
克服药物障碍的新型小分子疟疾药物的临床前开发
  • 批准号:
    8647555
  • 财政年份:
    2011
  • 资助金额:
    $ 21.48万
  • 项目类别:
Pre-clinical Safety and Efficacy of Reversed Chloroquines
反向氯喹的临床前安全性和有效性
  • 批准号:
    8144570
  • 财政年份:
    2010
  • 资助金额:
    $ 21.48万
  • 项目类别:
Reversed Chloroquines as Antimalarial Agents
逆转氯喹作为抗疟药
  • 批准号:
    7256755
  • 财政年份:
    2007
  • 资助金额:
    $ 21.48万
  • 项目类别:
Designed Antimalarial Agents Overcoming Chloroquine-Resistance
设计克服氯喹耐药性的抗疟药物
  • 批准号:
    7220473
  • 财政年份:
    2007
  • 资助金额:
    $ 21.48万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了